Maravai LifeSciences Holdings, Inc. is a life sciences company. Co. provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. Co. operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The MRVI average annual return since 2020 is shown above.
The Average Annual Return on the MRVI average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MRVI average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MRVI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|